UBS Group
BBIO icon

UBS Group’s BridgeBio Pharma BBIO Stock Holding History

UBS Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,200
Closed -$70K – 10244
2021
Q4 		$70K Buy
+4,200
New +$178K ﹤0.01% 6619

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's BBIO Position: Q1 2026 in Review

UBS Group increased its BridgeBio Pharma (BBIO) stake by 8.1% in Q1 2026, buying an estimated $11M and bringing the position to 2,026,821 shares worth $151M. The position accounts for 0.02% of the portfolio, ranked #769.

UBS Group first reported a position in BBIO in Q2 2019 and has held it in 28 quarters since. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • UBS Group held 2,026,821 shares of BridgeBio Pharma worth $151M as of Q1 2026.
  • UBS Group bought 151,156 BridgeBio Pharma shares in Q1 2026, an estimated $11M.
  • BridgeBio Pharma made up 0.02% of UBS Group's portfolio in Q1 2026, its #769 holding.
  • UBS Group first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 28 quarters since.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.